NCT03208465View on ClinicalTrials.gov

Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 7, 2017

Primary Completion Date

August 1, 2019

Study Completion Date

August 1, 2019

Conditions
Diabetes MellitusCoronary Disease
Interventions
DRUG

Empagliflozin

In empagliflozin group, patients will be prescribed empagliflozin 10mg/day.

DRUG

Sitagliptin

In sitagliptin group, patients will be prescribed sitagliptin 100mg/day.

Trial Locations (1)

Unknown

Asan Medical Center, Seoul

All Listed Sponsors
lead

CHEOL WHAN LEE, M.D., Ph.D

OTHER

NCT03208465 - Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease | Biotech Hunter | Biotech Hunter